磷脂酰乙醇水平区分脂肪性肝病亚型并与主要肝脏结局风险相关
在瑞典斯德哥尔摩2012至2020年接受PEth检测的46406人中开展队列研究,6377例推测MASLD患者中20% PEth 0.05-0.30 μmol/L提示过量饮酒(MetALD)、13% >0.30 μmol/L提示酒精相关肝病(ALD);PEth升高与主要不良肝脏结局风险相关,ALD患者PEth最高且预后最差。
要点
- PEth是近期饮酒的特异性生物标志物,可用于区分SLD亚型,尤其是ALD。
- 推测MASLD患者中20% PEth 0.05-0.30 μmol/L(MetALD)、13% >0.30 μmol/L(ALD)。
- PEth 0.05-0.30 μmol/L者MALO累积发生率高于PEth <0.05 μmol/L者。
核心结论
- PEth是区分SLD亚型(尤其ALD)的有价值酒精生物标志物,并可预测伴或不伴SLD者的不良结局。
研究设计与样本
- 队列研究,纳入2012至2020年瑞典斯德哥尔摩接受PEth检测者46406人,含各SLD亚型患者及无SLD者。
- 采用竞争风险计算各组MALO累积发生率,用Cox回归评估基线PEth水平与MALO发生的关联。
主要发现
- 6377例推测MASLD患者中,1294例(20%)基线PEth 0.05-0.30 μmol/L(35-210 ng/ml)提示过量饮酒(MetALD),854例(13%)>0.30 μmol/L提示ALD。
- MASLD且PEth 0.05-0.30 μmol/L者中位FIB-4和肝硬化患病率与PEth <0.05 μmol/L者相似。
- PEth 0.05-0.30 μmol/L者MALO累积发生率高于PEth <0.05 μmol/L者。
- 无肝硬化患者中,校正年龄、性别、SLD亚型和FIB-4后,PEth升高仍与MALO发生率显著更高相关。
- ALD患者PEth水平最高且预后最差。
关键数值与推荐
- PEth 0.05-0.30 μmol/L(35-210 ng/ml)提示过量饮酒,对应MetALD。
- PEth >0.30 μmol/L提示酒精相关肝病(ALD)。
临床怎么用
- 作者认为将PEth检测整合入常规诊断评估可增进对SLD病理生理的认识、减少误分类,并通过使临床医生提供适当治疗而最终改善患者结局。
- 作者指出需进一步研究在其他人群中验证这些发现,并探索将PEth纳入更广泛的SLD管理临床指南。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Phosphatidylethanol (PEth) is an ethanol metabolite used as a specific biomarker for recent alcohol consumption. We aimed to determine the proportion of patients with or at risk for metabolic dysfunction-associated steatotic liver disease (MASLD) who had PEth levels indicative of harmful alcohol consumption, and to assess associations between PEth levels and the risk of major adverse liver outcomes (MALOs). METHODS: We conducted a cohort study involving persons tested for PEth in Stockholm, Sweden between 2012 and 2020 (N = 46,406), including patients with various steatotic liver disease (SLD) subtypes and individuals without SLD. Cumulative incidences of MALOs were calculated for the different groups while accounting for competing risk. Cox regression was used to evaluate the association between baseline PEth levels and the incidence of MALOs. RESULTS: Among 6,377 patients with presumed MASLD, 1,294 (20%) had baseline PEth levels between 0.05 and 0.30 μmol/L (35-210 ng/ml), indicating excessive alcohol intake (MetALD), while 854 patients (13%) had values >0.30 μmol/L, indicating alcohol-related liver disease (ALD). Patients with MASLD and PEth levels between 0.05-0.30 μmol/L had similar median FIB-4 and cirrhosis prevalence as those with MASLD and PEth levels <0.05 μmol/L. However, patients with PEth levels between 0.05-0.30 μmol/L had higher cumulative incidences of MALOs compared to those with PEth levels <0.05 μmol/L. Elevated PEth levels were linked to significantly higher rates of MALOs in patients without cirrhosis, even after adjustments for age, sex, SLD subtype, and FIB-4. Patients with ALD had the highest PEth levels and worst prognosis. CONCLUSIONS: PEth is a valuable alcohol biomarker for distinguishing between SLD subtypes, especially ALD, and predicts adverse outcomes in people with and without SLD. IMPACT AND IMPLICATIONS: There is controversy regarding the various proposed steatotic liver disease (SLD) subtypes, with the most recent definition suggesting that patients with elevated alcohol consumption and MASLD should be classified as having MetALD. Here, we address this challenge by classifying patients with SLD using phosphatidylethanol (PEth), a direct and reliable biomarker for recent alcohol consumption. Our analysis of 46,406 patients revealed that PEth may be a valuable tool for distinguishing between MASLD and MetALD, and that PEth is strongly associated with the risk of liver outcomes in individuals with and without known SLD. Integrating PEth testing into routine diagnostic evaluations could enhance knowledge on the underlying pathophysiology in SLD, reduce the potential for misclassification, and ultimately improve patient outcomes by enabling clinicians to offer appropriate therapies. Further research is needed to validate these findings in other populations and to explore the potential integration of PEth into broader clinical guidelines for managing SLD.
引用
- Vaz J, Nasr P, Helander A, et al. Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes. J Hepatol. 2025. PMID: 40228582. doi:10.1016/j.jhep.2025.04.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。